Authors Say Contrast-Enhanced CT Safe for Most Patients

September 10, 2014 — According to new research performed at the Mayo Clinic, iodine-based contrast material injected intravenously to enhance computed tomography (CT) images can be safely used in most patients. The study appears online in the journal Radiology.

Of the 80 million or more CT scans performed each year in the United States, iodine-based contrast material is used in at least half to enhance CT images, according to researcher Robert J. McDonald, M.D., Ph.D., a radiology resident at the Mayo Clinic in Rochester, Minn.

According to McDonald, a small number of case reports from the 1950s and, more recently, retrospective studies lacking appropriate control groups causally linked the use of iodine-based contrast CTs to kidney damage, a condition called contrast-induced nephropathy.

“For nearly 60 years, physicians have worried about contrast-induced nephropathy when using iodinated contrast material, particularly for patients with impaired kidney function,” McDonald said. “Emerging evidence now suggests these concerns are likely vastly overestimated.”

McDonald and a team of researchers analyzed information on patients who underwent abdominal, pelvic and thoracic CT scans at the Mayo Clinic between 2000 and 2010. A study group of 21,346 patients included 10,673 patients who each underwent a contrast-enhanced CT exam and 10,673 patients who underwent a similar CT without intravenous contrast. The two groups were closely matched by demographic and clinical characteristics, including gender, race and pre-existing conditions such as diabetes, congestive heart failure and acute renal disease.

The researchers analyzed the patient data for adverse events following the CT scans, including acute kidney injury, the need for emergency renal dialysis (in patients with no prior history of dialysis) and death within 30 days of contrast exposure.

The analysis revealed no significant difference in the rate of acute kidney injury between patients in the contrast group (4.8 percent, or 515 of 10,673) and the non-contrast group (5.1 percent or 544 of 10,673). More importantly, the rates of emergency dialysis and death in the 30-day window following CT examination were not significantly different between patients exposed to contrast and those who were not exposed. These results were also observed among patients with compromised kidney function and high-risk conditions, such as congestive heart failure and diabetes, which are assumed to predispose a patient to kidney injury.

“These results challenge long-held assumptions regarding the presumed nephrotoxic risk of intravenous contrast material,” McDonald said. “We hope that our findings will help refine the safety profile of these contrast agents."

For more information: www.radiologyinfo.org

Related Content

News | Coronavirus (COVID-19)

November 29, 2021 — The largest multi-institutional international study to date on brain complications of COVID-19 has ...

Time November 29, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Lunit, a medical AI provider, is returning to the 107th Radiological Society of North America (RSNA) ...

Time November 28, 2021
arrow
News | Computed Tomography (CT)

November 28, 2021 — Detection Technology, a leader in X-ray detector solutions, unveiled the industry’s first off-the ...

Time November 28, 2021
arrow
News | Computed Tomography (CT)

November 28, 2021 — Royal Philips, a leader in health technology, unveiled its vision for interventional medicine by ...

Time November 28, 2021
arrow
News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 17, 2021 — Lunit, a leading medical artificial intelligence (AI) provider, announced it has received U.S. Food ...

Time November 17, 2021
arrow
News | Digital Pathology

November 15, 2021 — Saltus Biotech, a leader in 8k image technology, introduces a new high-end computer workstation and ...

Time November 15, 2021
arrow
Videos | Radiation Therapy

Siemens and Philips demonstrated examples of new imaging software to convert MRI datasets into synthetic computed ...

Time November 15, 2021
arrow
Subscribe Now